Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis
Jan, V.; Vaillant, L.; Bressieux, J.M.; Barthélemy, H.; Legoux, A.; Steiner, H.G.; Reigneau, O.
European Journal of Dermatology Ejd 9(8): 615-617
1999
ISSN/ISBN: 1167-1122 PMID: 10586127 Document Number: 507631
Cyclosporin is an effective treatment for psoriasis but its efficacy is only palliative. The aim of this study was to evaluate the percentage of patients in whom a short term therapy may be used without relapse after discontinuation of cyclosporin. In this multicenter, open, non-controlled study fifty-eight patients were included who had severe and extensive chronic plaque-type psoriasis. Treatment duration was 28 weeks. The absence of relapse was defined as the requirement to resume systemic treatment at 16 weeks after discontinuation of Sandimmun . The overall efficacy of Sandimmun at W20 was 72%. No relapse or premature withdrawal occurred in 18 cases out of 39 (47%). In these cases local treatment was sufficient following discontinuation. Thus we show the potential value of a single 5 month course of cyclosporin treatment. In this study tapering of cyclosporin was not useful. In 50% of cases short-term cyclosporin treatment was not followed by resumption of systemic treatment and constitutes an improvement in qualify of life.